Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
AERIE PHARMACEUTICALS INC (AERI) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/10/2023 SC 13G/A Flynn James E reports a 0% stake in Aerie Pharmaceuticals, Inc.
12/01/2022 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/21/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Amended and Restated Certificate of Incorporation of Aerie Pharmaceuticals, Inc",
"each outstanding Share of restricted stock of the Company (a “Company Restricted Stock”) that vested solely on the passage of time, whether or not vested, was cancelled and the holder thereof became entitled to receive a cash payment equal to the Merger Consideration with respect to each Share of time-vested Company Restricted Stock, whether or not vested, held by such holder (without regard to vesting);",
"First Supplemental Indenture, by and between Aerie Pharmaceuticals, Inc. and Wilmington Trust, National Association"
11/21/2022 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/18/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/10/2022 SC 13G/A MORGAN STANLEY reports a 0.8% stake in AERIE PHARMACEUTICALS INC
11/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/07/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/07/2022 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
09/21/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Overview Presentation dated September 2022"
08/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among the Company, Parent and Merger Sub",
"Agreement and Plan of Merger, by and among the Company, Parent and Merger Sub"
08/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update"
08/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease"
06/13/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy